Module 4 - Condition-Specific Nutrition Support (V.5) Flashcards
A patient with acute kidney injury (AKI) who requires parenteral nutrition support would most likely benefit from a solution containing which of the following?
A. Essential amino acids only
B. Essential amino acids with arginine only
C. Essential amino acids and nonessential amino acids
D. Essential amino acids and branched-chain amino acids
C. Essential amino acids and nonessential amino acids
Early clinical studies suggested that patients receiving a parenteral solution of essential amino acids (EAA) and dextrose could reduce need for dialysis. Subsequent studies comparing EAA to a mixture of EAA and nonessential amino acids showed no difference in the rate or frequency of recovery from AKI or survival. Formulations providing only EAA are not recommended. Branched-chain amino acids have demonstrated no advantage over standard amino acids in patients with AKI. Several nonessential amino acids, including tyrosine, arginine, and glutamine become conditionally essential in AKI.
Which of the following types of fistulas will result in the greatest degree of nutritional loss?
A. Distal low output
B. Distal high output
C. Proximal low output
D. Proximal high output
D. Proximal high output
The higher the fistula occurs in the gastrointestinal tract, the greater the output and the higher the risk of metabolic derangements, as seen with proximal high output fistulas. Fluids and electrolytes will need to be managed and replaced carefully. Protein and calorie requirements may be elevated due to nutrient losses via fistula drainage and/or sepsis. Enteral nutrition may be possible in low output fistulas (< 500 mL/d) with distal enteral access and can be fed with a fiber containing formula. To minimize fistula output in distal ileal or colonic fistulas a fiber free or low fiber formula should be used and the site should be as high up as possible to increase the surface area for absorption
Which of the following is a major contributing factor in the development of metabolic bone disease in patients with inflammatory bowel disease?
A. Corticosteroid use
B. Aluminum toxicity
C. Vitamin B12 deficiency
D. Oxalic acid deficiency
A. Corticosteroid use
Osteopenia and osteoporosis are metabolic bone disease complications associated with inflammatory bowel disease. Although it is controversial whether or not the primary contributor is corticosteroid therapy, a correlation has been shown between corticosteroid dose and degree of osteopenia. Supplementation of calcium and vitamin D reduces osteopenia in patients on long-term steroids.
Malnutrition, vitamin D deficiency, corticosteroid therapy, magnesium deficiency, and chronic inflammation, commonly found in patients with inflammatory bowel disease, are also associated with the development of metabolic bone disease.
Hypercalciuria, aluminum toxicity and magnesium deficiency may be associated with parenteral nutrition-associated metabolic bone disease and could be a factor for patients with inflammatory bowel disease who require long-term parenteral nutrition.
Aluminum toxicity and malabsorption are probably minor contributors to the problem in patients with inflammatory bowel disease.
Vitamin B12 and oxalic acid play no known role in metabolic bone disease.
In patients with severe acute pancreatitis, the use of enteral nutrition via nasojejunal feeding tube rather than parenteral nutrition is associated with
A. an increased incidence of hyperglycemia.
B. a lower risk of developing infectious complications.
C. a greater incidence of negative nitrogen balance.
D. a decreased frequency of pancreatic stimulation.
B. a lower risk of developing infectious complications.
Severe acute pancreatitis has historically been considered an indication for parenteral nutrition in an effort to avoid enterally induced pancreatic stimulation; however, more recent research has demonstrated that enteral nutrition is well tolerated in severe acute pancreatitis. In a study of 38 patients with severe acute pancreatitis, enteral nutrition beyond the ligament of Treitz was compared with parenteral nutrition. Those who received enteral nutrition were less likely to develop infectious complications, maintained equal nitrogen balance and had a reduced incidence of hyperglycemia compared to those who received parenteral nutrition. The enteral feedings were well tolerated without adverse effects on the disease course. It is suggested that the enteral route be used preferentially, rather than parenteral nutrition, for the patient with severe acute pancreatitis. The 2013 American College of Gastroenterology Guidelines for Management of Acute Pancreatitis recommends administration of enteral nutrition as the preferred route of nutrition support to prevent infectious complications, unless EN is not available, tolerated or patient is not meeting nutritional requirements via EN alone.
What is the glomerular filtration rate (GFR) of a patient with end-stage renal disease?
A. >90 mL/min/1.73 m2
B. 30-59 mL/min/1.73 m2
C. 15-29 mL/min/1.73 m2
D. <15 mL/min/1.73 m2
D. <15 mL/min/1.73 m2
Stage 1, Kidney damage with normal or high GFR: >90 mL/minute/1.73 m2.
Stage 2, Kidney damage with mild low GFR: 60-89 mL/minute/1.73 m2.
Stage 3, Moderate low GFR: 30-59 mL/minute/1.73 m2.
Stage 4, Severe low GFR: 15-29 mL/minute/1.73 m2.
Stage 5, Kidney failure: <15 (or dialysis) mL/minute/1.73 m2.
In the first 1 - 3 months after a bone marrow transplant the nutritional needs of a patient are best met with
A. 20-25 kcal/kg daily with >= 1.5 g protein per kg body weight.
B. 20-25 kcal/kg daily with 80% of total calories from carbohydrate.
C. 30-35 kcal/kg daily with >= 1.5 g protein per kg body weight.
D. 30-35 kcal/kg daily with 80% of total calories from carbohydrate.
C. 30-35 kcal/kg daily with >= 1.5 g protein per kg body weight.
Energy needs will vary with the individual, but energy requirements are usually estimated at 1.5 x basal energy expenditure (BEE), or approximately 30 to 35 kcal per kilogram. Protein intake should be aimed at 1.5 g per kilogram during the first 1 to 3 months after transplantation.
In pulmonary insufficiency, excessive calorie administration may cause increased blood pCO2 resulting in
A. metabolic acidosis.
B. metabolic alkalosis.
C. respiratory acidosis.
D. respiratory alkalosis.
C. respiratory acidosis.
Respiratory acidosis results from disorders producing alterations in ventilatory control, increased production of CO2, and respiratory muscle weakness. The increased CO2 production is greatest when overfeeding occurs (2 x BEE) due to an excess generation of CO2 relative to O2 consumption during carbohydrate metabolism.
In patients with burns, providing caloric support above energy expenditure has been found to
A. significantly decrease hospital length of stay.
B. improve wound healing and graft success.
C. decrease fat accumulation and steatosis.
D. have no effect on preservation of lean body mass.
D. have no effect on preservation of lean body mass.
The metabolic stress that occurs in burn injury generates a hypercatabolic state that increases energy expenditure. Although patients with burns have increased needs, feeding in excess of energy expenditure may cause hyperglycemia, hepatic steatosis, and prolonged ventilator dependence. One study of critically ill burn patients showed that caloric delivery beyond 1.2 x measured resting energy expenditure did not conserve lean body mass but was associated with increased fat mass accumulation.
Nutrition support for solid-organ transplant patients receiving cyclosporine may need to be modified due to the presence of
A. hyperkalemia.
B. hypoglycemia.
C. hypermagnesemia.
D. hypocholesterolemia.
A. hyperkalemia.
Cyclosporine, commonly used after solid organ transplantation for immune suppression, can frequently cause nutrient disorders such as hyperkalemia, hypomagnesemia, hyperglycemia, and hypercholesterolemia, and has a direct effect on the renin-angiotensin-aldosterone system contributing to altered potassium homeostasis. Cyclosporine also affects the renal tubular excretion of potassium. Patients taking cyclosporine should be educated on dietary potassium intake and should have serum potassium levels monitored on a regular basis.
Human immunodeficiency virus (HIV) associated lipodystrophy syndrome is most commonly associated with which of the following classes of agents used to treat HIV infection
A. integrase strand transfer inhibitors (INSTIs).
B. non-nucleoside reverse transcriptase inhibitors (NNRTIs).
C. nucleoside reverse transcriptase inhibitors (NRTIs).
D. protease inhibitors (PIs).
C. nucleoside reverse transcriptase inhibitors (NRTIs).
HIV-associated lipodystrophy syndrome is manifested by subcutaneous adipose tissue loss with visceral adipose tissue sparing or accumulation. Subcutaneous tissue loss is often most evident in the face, buttocks, and lower extremities. Lipodystrophic patients may also be insulin resistant . Lipodystrophy has been strongly associated with first-generation nucleoside reverse transcriptase inhibitors.
Which of the following are counter-regulatory hormones responsible for the hypercatabolism observed in critically ill trauma patients?
A. Glycogen, insulin, norepinephrine
B. Glucagon, epinephrine, cortisol
C. Glycerol, serotonin, thymoglobulin
D. Glycerin, leptin, adenosine
B. Glucagon, epinephrine, cortisol
The inflammation following a traumatic injury provokes a release of systemic catabolic hormones including epinephrine, glucagon, and cortisol. These hormones are responsible for glycogenolysis, gluconeogenesis, proteolysis, and free fatty acid release. The goal of this metabolic response by the patient is to maintain survival and homeostasis, and to promote recovery. Therapeutic intervention is geared toward blunting the inflammatory response without making the patient susceptible to immunosuppression. Timely resuscitation, including restoration of perfusion, oxygenation, and hemodynamic stability, is the top priority. The early initiation of nutrition is an important component of supportive therapy in the care of the trauma patient.
A critically ill hyperglycemic patient receiving continuous enteral nutrition with a history of insulin dependent diabetes should ideally be placed on
A. prandial subcutaneous insulin.
B. oral glucose-lowering agents given via the feeding tube.
C. continuous IV insulin infusion.
D. correction (sliding scale) subcutaneous insulin.
C. continuous IV insulin infusion.
Insulin should be used to treat diabetes during enteral nutrition. In the critical care setting, continuous intravenous insulin infusion has been shown to be the best method for achieving glycemic targets and allows for off cycles during the 24-hour period when enteral feeding is held or discontinued.
Which of the following immunomodulating nutrients may be harmful in patients with sepsis/septic shock?
A. Arginine
B. Selenium
C. Nucleic acids
D. Omega-3 fatty acids
A. Arginine
Arginine is a major substrate for nitric oxide production. Under normal conditions, small quantities of nitric oxide have a beneficial effect on immune function and tissue oxygenation. Thus, arginine is considered an “immune-enhancing” agent. However, nitric oxide can also be detrimental by leading to coagulation abnormalities and altered hemodynamic status. In this case, arginine could be considered harmful for patients with sepsis/septic shock. Because of these effects, there is still much debate over the value of arginine in nutrition support for critically ill patients.
Patients with short bowel syndrome would benefit most from octreotide injections in the presence of
A. recent bowel resection with loss of ileocecal valve
B. short bowel secondary to mesenteric ischemia.
C. short bowel secondary to inflammatory bowel disease.
D. refractory diarrhea not controlled with diet and medication.
D. refractory diarrhea not controlled with diet and medication.
Octreotide reduces the production of a variety of GI secretions and slows jejunal transit. However, its effects are often short lasting and have not been shown to improve absorption or lead to the elimination of the need for parenteral nutrition. Due to an increased risk for cholelithiasis, expense and the potential for octreotide to inhibit bowel adaptation, use of octreotide should be reserved for patients with large volume stool losses in whom fluid and electrolyte management is problematic and should be avoided in the early adaptation stage.
Which of the following best describes enteral glutamine supplementation in the critically ill patient in multi organ failure?
A. Enteral glutamine decreases mortality
B. Enteral glutamine decreases ventilator days
C. Enteral glutamine decreases hospital length of stay
D. Enteral glutamine decreases nosocomial infections
D. Enteral glutamine decreases nosocomial infections
A recent meta-analysis investigated the impact of glutamine-supplemented nutrition on the outcomes of critically ill patients and found that glutamine supplementation did not decrease mortality and length of hospital stay in critically ill patients. However, glutamine supplementation did reduce nosocomial infections among critically ill patients.
Which of the following is true of essential fatty acid deficiency (EFAD) in patients with cystic fibrosis (CF)?
A. Routine supplementation of omega-3 fatty acids is essential in the management of CF
B. EFAD usually does not manifest in CF patients until the second decade.
C. CF patients without pancreatic insufficiency rarely develop EFAD
D. EFA profiles have been shown to improve in CF patients after lung transplantation
D. EFA profiles have been shown to improve in CF patients after lung transplantation
Disruption in the exocrine function of the pancreas leads to malabsorption of fat, protein, and fat-soluble vitamins in CF patients. Essential fatty acid deficiency may contribute to inflammatory pathways contributing to the pulmonary and gastrointestinal symptoms associated with CF. The overt signs of EFAD (scaly dermatitis, alopecia, thrombocytopenia, and growth failure) are uncommon in patients with CF. EFAD correlates with poor growth and pulmonary status. EFA status is usually evaluated by measuring the triene: tetraene ratio. Although supplementation with omega 3 fatty acids are sometimes used in the management of CF, results from clinical trials have shown mixed results and further trials are needed to determine the efficacy of routine EFA supplementation in the management of CF.
What is the most appropriate feeding strategy for a morbidly obese trauma patient?
A. High protein, hypocaloric feeding
B. High protein, hypercaloric feeding
C. Low protein, hypocaloric feeding
D. Low protein, hypercaloric feeding
A. High protein, hypocaloric feeding
Data on nutrition support in obese patients support the hypocaloric, high protein feeding strategy. High-protein hypocaloric feeding is thought to maintain nitrogen balance and lean body mass while facilitating the mobilization of adipose tissue for fuel utilization. Hypercaloric feeding would likely result in hyperglycemia and difficulty weaning from the ventilator.
ERAS (Enhanced Recovery After Surgery) is a care program that has been shown to improve outcomes after major surgery. The key mechanism behind the ERAS effectiveness is:
A. comprehensive preoperative nutrition counseling.
B. decrease the stress of surgery and support recovery.
C. decreased NPO duration and optimized nutrition before/after surgery.
D. the multi-professional and multidisciplinary approach.
B. decrease the stress of surgery and support recovery.
ERAS is an elaborate pre- and postoperative care program. Objectives are to avoid starvation, decrease the stress of surgery (which induces insulin resistance) and limit postoperative IVF while optimizing pain control and GI function and mobilization. The nutrition components are to avoid pre-op fasting by providing CHO nutrition/fluid and withholding routine bowel prep. Patients receive less IVF and experience fewer post-op complications. ERAS was originally designed for elective colon resection surgeries.